Theragnostic Imaging Using Radiolabeled Antibodies and Tyrosine Kinase Inhibitors

During the past decade, the efficacy of new molecular targeted drugs such as tyrosine kinase inhibitors (TKIs) and monoclonal antibodies has been proven worldwide, and molecular targeted therapies have become the mainstream in cancer therapy. However, clinical use of these new drugs presents unexpec...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshimoto, Mitsuyoshi, Kurihara, Hiroaki, Fujii, Hirofumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4385703/
https://www.ncbi.nlm.nih.gov/pubmed/25874259
http://dx.doi.org/10.1155/2015/842101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4385703/
https://www.ncbi.nlm.nih.gov/pubmed/25874259
http://dx.doi.org/10.1155/2015/842101

Ejemplares similares